Search Results - "cadonilimab"

  • Showing 1 - 7 results of 7
Refine Results
  1. 1
    Clinical progress of cadonilimab in the treatment of malignant tumor

    Clinical progress of cadonilimab in the treatment of malignant tumor by ZHANG Xiaoqing, LIU Shuai, ZHANG Kai, WANG Yuchao, HE Jing, LUAN Wei

    Published 2025-06-01

    Cadonilimab is a programmed death-1 (PD-1) and cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) bispecific antibody independently developed in China, and is also the world's first approved PD-1/CTLA-4 bispecific antibody. By simultaneously blocking two immunosuppressive pathways, PD-1/CTLA-...

    Full description

    Subjects: “…cadonilimab…”
    Get full text
    Article

    Save to List
    Saved in:
  2. 2
    Case Report: Cadonilimab plus anlotinib with radiotherapy for lung adenocarcinoma with pancreatic metastasis in later-line therapy

    Case Report: Cadonilimab plus anlotinib with radiotherapy for lung adenocarcinoma with pancreatic metastasis in later-line therapy by Jianquan Yang, Zixin Li, Xuezhou Pang, Yakun Zhang, Beilei Zeng, Yan Gui, Daiyuan Ma

    Published 2025-07-01

    Patients with advanced lung adenocarcinoma lacking driver gene mutations face the clinical dilemma of limited treatment options and poor prognosis in later-line therapy. Although immune checkpoint inhibitors (ICIs) combined with anti-angiogenic agents offer a promising approach, the optimal treatmen...

    Full description

    Subjects: “…cadonilimab…”
    Get full text
    Article

    Save to List
    Saved in:
  3. 3
    Cost-effectiveness analysis of cadonilimab plus bevacizumab and chemotherapy for persistent, recurrent, or metastatic cervical cancer

    Cost-effectiveness analysis of cadonilimab plus bevacizumab and chemotherapy for persistent, recurrent, or metastatic cervical cancer by Kaixuan Wang, Shixian Liu, Ruixue Wang, Lei Dou, Jie Gao

    Published 2025-06-01

    ObjectiveThe aim of this study is to investigate the cost-effectiveness of cadonilimab plus bevacizumab and chemotherapy in the first-line treatment for patients with persistent, recurrent, or metastatic cervical cancer from a healthcare system perspective in China.MethodsA partitioned survival mode...

    Full description

    Subjects: Get full text
    Article

    Save to List
    Saved in:
  4. 4
    Efficacy and safety of Cadonilimab plus anlotinib in small cell lung cancer with brain metastases

    Efficacy and safety of Cadonilimab plus anlotinib in small cell lung cancer with brain metastases by Hai-Zhen Yi, Wei Lv, Jin-Jing Chen, Zhan Lin

    Published 2025-07-01

    PurposeThis study aimed to evaluate the efficiency and safety of Cadonilimab and Anlotinib pairing in individuals diagnosed with small cell lung cancer (SCLC) and brain metastases (BMs).MethodsA review was performed on individuals who were diagnosed with small cell lung cancer (SCLC) and had central...

    Full description

    Subjects: Get full text
    Article

    Save to List
    Saved in:
  5. 5
    Cost-effectiveness analysis of cadonilimab plus chemotherapy as a first-line treatment option in HER-2-negative advanced gastric cancer

    Cost-effectiveness analysis of cadonilimab plus chemotherapy as a first-line treatment option in HER-2-negative advanced gastric cancer by Longfeng Zhang, Qingsheng Yang, Zhiwei Zheng

    Published 2025-07-01

    ObjectiveThis study aims to evaluate the cost-effectiveness of using cadonilimab plus chemotherapy compared to chemotherapy in HER-2-negative advanced gastric cancer from the perspective of the Chinese healthcare system.MethodsA cost-effectiveness analysis was conducted utilizing a partitioned survi...

    Full description

    Subjects: Get full text
    Article

    Save to List
    Saved in:
  6. 6
    Cadonilimab in combination with chemotherapy for HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a cost-effectiveness analysis

    Cadonilimab in combination with chemotherapy for HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a cost-effectiveness analysis by Zuojuan Xiang, Wei Li, Qiao Xia

    Published 2025-07-01

    BackgroundThe COMPASSION-15 trial confirmed the safety and effectiveness of cadonilimab, a bispecific antibody targeting both programmed death 1 (PD-1) and cytotoxic T lymphocyte antigen-4 (CTLA-4), in treating human epidermal growth factor receptor 2 (HER2) negative advanced gastric or gastroesopha...

    Full description

    Subjects: “…cadonilimab…”
    Get full text
    Article

    Save to List
    Saved in:
  7. 7
    Real-world data of cadonilimab in recurrent or metastatic cervical cancer in China: a multicentric study

    Real-world data of cadonilimab in recurrent or metastatic cervical cancer in China: a multicentric study by Jian Chen, Haijuan Yu, Yingtao Lin, Dan Hu, Li Liu, Renliang Fan, Jianping Zou, Lele Zang, Yao Lin, Rong Lin, Dezhao Chen, Xiaoying Weng, Fenfang Shen, Shaoyu Wang, Wei Zeng, Qihua Tian, Yun Yi, Yuanfeng Chen, Jinjin Miao, Bo Zhang, Yinxia Zou, Fengming Gao, Fengming Gao, Rong Lian, Lin Yang, Yang Sun

    Published 2025-07-01

    BackgroundImmunotherapy has become a powerful clinical strategy for treating recurrent or metastatic cervical cancer (R/M CC). Cadonilimab, a novel anti-PD-1/CTLA-4 bispecific antibody, has shown substantial clinical benefits in cancer treatment. However, there is no real-world evidence of cadonilim...

    Full description

    Subjects: Get full text
    Article

    Save to List
    Saved in:

Search Tools: